Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer

Past studies have demonstrated that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors can significantly improve clinical outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and sensitive EGFR gene mutations. Gefitinib (Iressa(®)), the first or...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Ying, Li, Xiao-Fen, Chen, Jia-Qi, Dong, Cai-Xia, Weng, Shan-Shan, Huang, Jian-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045263/
https://www.ncbi.nlm.nih.gov/pubmed/24920926
http://dx.doi.org/10.2147/OTT.S34124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045263/
https://www.ncbi.nlm.nih.gov/pubmed/24920926
http://dx.doi.org/10.2147/OTT.S34124

Ejemplares similares